King Luther Capital Management Corp raised its holdings in shares of Cambrex Corporation (NYSE:CBM) by 11.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 70,865 shares of the biotechnology company’s stock after purchasing an additional 7,146 shares during the period. King Luther Capital Management Corp owned 0.22% of Cambrex Corporation worth $4,234,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Flinton Capital Management LLC raised its position in shares of Cambrex Corporation by 3.8% in the 1st quarter. Flinton Capital Management LLC now owns 1,870 shares of the biotechnology company’s stock worth $103,000 after acquiring an additional 68 shares in the last quarter. Creative Planning raised its position in shares of Cambrex Corporation by 162.6% in the 2nd quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 1,093 shares in the last quarter. Nisa Investment Advisors LLC raised its position in shares of Cambrex Corporation by 9.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 150 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Cambrex Corporation in the 1st quarter worth approximately $109,000. Finally, Ameritas Investment Partners Inc. bought a new position in shares of Cambrex Corporation in the 1st quarter worth approximately $151,000. 98.28% of the stock is owned by institutional investors and hedge funds.
Shares of Cambrex Corporation (NYSE:CBM) opened at 53.60 on Friday. The firm’s 50-day moving average price is $53.51 and its 200 day moving average price is $55.12. Cambrex Corporation has a 52 week low of $38.30 and a 52 week high of $62.95. The stock has a market capitalization of $1.75 billion, a P/E ratio of 19.53 and a beta of 2.25.
Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, hitting analysts’ consensus estimates of $0.76. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The company had revenue of $134.55 million during the quarter, compared to the consensus estimate of $136.82 million. During the same quarter in the previous year, the firm posted $0.68 earnings per share. Cambrex Corporation’s revenue for the quarter was up 13.4% compared to the same quarter last year. Analysts expect that Cambrex Corporation will post $3.08 earnings per share for the current year.
In other Cambrex Corporation news, CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction on Friday, September 1st. The shares were sold at an average price of $51.53, for a total value of $618,360.00. Following the transaction, the chief executive officer now directly owns 95,328 shares of the company’s stock, valued at $4,912,251.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 36,000 shares of company stock worth $2,070,960 over the last ninety days. Corporate insiders own 2.48% of the company’s stock.
Several research firms recently weighed in on CBM. BidaskClub downgraded Cambrex Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. ValuEngine downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $64.00.
TRADEMARK VIOLATION NOTICE: “Cambrex Corporation (CBM) Holdings Lifted by King Luther Capital Management Corp” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://ledgergazette.com/2017/09/17/cambrex-corporation-cbm-holdings-lifted-by-king-luther-capital-management-corp.html.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.